GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTKGet Free Report) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 165,864 shares, a decrease of 93.5% from the July 30th total of 2,555,155 shares. Based on an average trading volume of 7,214,843 shares, the short-interest ratio is currently 0.0 days. Currently, 2.3% of the company’s stock are short sold.

GlucoTrack Stock Performance

GCTK stock traded up $0.01 during trading hours on Tuesday, reaching $0.34. The stock had a trading volume of 558,349 shares, compared to its average volume of 25,615,654. The stock has a 50-day simple moving average of $0.39 and a 200 day simple moving average of $0.77. GlucoTrack has a fifty-two week low of $0.25 and a fifty-two week high of $14.14. The stock has a market capitalization of $2.63 million, a PE ratio of -0.04 and a beta of 0.70. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.46 and a quick ratio of 0.46.

GlucoTrack (NASDAQ:GCTKGet Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported $0.76 earnings per share for the quarter.

Analysts Set New Price Targets

GCTK has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Friday, July 17th. Wall Street Zen upgraded GlucoTrack from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Analysis on GlucoTrack

Hedge Funds Weigh In On GlucoTrack

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after buying an additional 4,085 shares during the period. Boothbay Fund Management LLC bought a new position in shares of GlucoTrack during the 4th quarter worth approximately $52,000. Finally, Ikarian Capital LLC bought a new position in shares of GlucoTrack during the 4th quarter worth approximately $177,000. Institutional investors own 10.92% of the company’s stock.

About GlucoTrack

(Get Free Report)

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.

See Also

Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.